Fertin Pharma A/S has reached another milestone in the development of nicotine replacement therapy (NRT) chewing gum with its newly issued patent for single-layered compressed gum technology, EP 2 229 158 B1.
In addition to this newly issued European patent, Fertin has three other issued European patents relevant to the field of single-layered compressed nicotine gum technology, including EP 1 761 243 B1, EP 1 817 014 B1, EP 2 296 486 B1. Furthermore, Fertin has in-licensed patents EP 1 523 241 B1 and EP 2 162 013 B1 from its sister company, Gumlink A/S. Apart from Europe, additional patents have been issued in other parts of the world, including the US and India.
Compressed nicotine gum is based on a technology where gum base or chewing gum granules are compressed either alone or in combination with additional tablet material in a tablet press machine. This technology differs from traditional extruded chewing gum technology in that the manufacturing process does not require heat. With this newly issued patent, Fertin continues to expand its large patent portfolio for both single and multi-layered compressed nicotine gum
Fertin Pharma A/S is a family-owned company based in Vejle, Denmark with additional facilities in India. Fertin is the world’s leading B2B developer/manufacturer of medicated chewing gum, specializing in nicotine replacement therapy gum.
For further information, please contact Ken Noguchi, VP BD, Sales and Marketing (email@example.com).